Search results
Results from the WOW.Com Content Network
The Comprehensive Drug Abuse Prevention and Control Act of 1970, Pub. L. 91–513, 84 Stat. 1236, enacted October 27, 1970, is a United States federal law that, with subsequent modifications, requires the pharmaceutical industry to maintain physical security and strict record keeping for certain types of drugs. [1]
The United States Drug Enforcement Administration (DEA) maintains lists regarding the classification of illicit drugs (see DEA Schedules).It also maintains List I of chemicals and List II of chemicals, which contain chemicals that are used to manufacture the controlled substances/illicit drugs.
A DEA number (DEA Registration Number) is an identifier assigned to a health care provider (such as a physician, physician assistant, nurse practitioner, optometrist, podiatrist, dentist, or veterinarian) by the United States Drug Enforcement Administration allowing them to write prescriptions for controlled substances.
The Drug Enforcement Administration was established on July 1, 1973, [4] by Reorganization Plan No. 2 of 1973, signed by President Richard Nixon on July 28. [5] It proposed the creation of a single federal agency to enforce the federal drug laws as well as consolidate and coordinate the government's drug control activities.
Diversion Investigator (DI) is the title of a specialist position within the Drug Enforcement Administration (DEA) of the United States Department of Justice.DIs are responsible for addressing the problem of diversion of controlled pharmaceuticals and regulated chemicals from the legitimate channels in which they are manufactured, distributed, and dispensed.
Walmart Inc. v. DEA-DOJ was a settlement involving the complaints and lawsuits of Walmart pharmacy, and other large pharmaceutical companies. The lawsuits were made after an official complaint issued by the United States Department of Justice and the Drug Enforcement Administration, after Walmart was accused of illicitly selling opioids to their customers.
A drug-therapy (related) problem can be defined as an event or circumstance involving drug treatment (pharmacotherapy) that interferes with the optimal provision of medical care. In 1990, L.M. Strand and her colleagues (based on the previous work of R.L Mikeal [ 3 ] and D.C Brodie, [ 4 ] published respectively in 1975 and 1980) classified the ...
Part of the problem was the CAFC's decision in Roche Products, Inc. v. Bolar Pharmaceutical Co., which interpreted existing U.S. law as prohibiting generic competitors from performing tests required for FDA approval using patented methods, until the patents expired. [2] In response, the Hatch-Waxman Act was negotiated and enacted. [3]